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Much of the original research on desmosomes and
their biochemical components was through analysis
of skin and mucous membranes. The identification of
desmogleins 1 and 3, desmosomal adhesion glyco-
proteins, as targets in pemphigus, a fatal autoimmune
blistering disease of the skin and mucous membranes,
provided the first link between desmosomes, desmo-
gleins, and human diseases. The clinical and histolo-
gical similarities of staphylococcal scalded skin
syndrome or bullous impetigo and pemphigus folia-
ceus led us to identify desmoglein 1 as the proteolytic
target of staphylococcal exfoliative toxins. Genetic
analysis of striate palmoplantar keratoderma and
hypotrichosis identified their responsible genes as
desmogleins 1 and 4, respectively. More recently,
these fundamental findings in cutaneous biology
were extended beyond the skin. Desmoglein 2, which
is expressed earliest among the four isoforms of
desmoglein in development and found in all desmo-
some-bearing epithelial cells, was found to be
mutated in arrythmogenic right ventricular cardio-
myopathy and has also been identified as a receptor
for a subset of adenoviruses that cause respiratory
and urinary tract infections. The story of desmoglein
research illuminates how dermatological research,
originally focused on one skin disease, pemphigus,
has contributed to understanding the biology and
pathophysiology of many seemingly unrelated tissues
and diseases.
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INTRODUCTION
The story of the discovery of desmogleins (Dsgs) in
desmosomes, their relationship with adhesion molecules,
and their targeting in diseases with loss of adhesion of cells is
one of beautiful simplicity and logic, in which the research in
skin has had a major role. This review will tell that story
(Table 1).
The story starts with the discovery of desmosomes by
electron microscopy and observations that they have a role in
adhesion of keratinocytes (KCs). Dermatologists already
know intuitively that desmosomes are important in cell
adhesion, because in spongiosis, one of the most common
pathologies seen in inflammatory skin diseases such as
allergic contact dermatitis, there is edema between KCs
separating their cell membranes, yet the cells stay attached
right at the desmosomes (also called in the past ‘‘intercellular
bridges’’). Only when the desmosomes finally ‘‘dissolve’’
does a spongiotic blister form. It was in skin and stratified
squamous epithelial tissue in which the presence and
importance of desmosomes was discovered, but subsequently
they were discovered in non-epithelial tissues such as heart
(see below).
Important JID references
Multiple authors. January 2007. Milestones Cutaneous Biology: Desmosome.
J Invest Dermatol E1–E16 (published online).
Multiple authors. October 2008. Milestones Cutaneous Biology: Autoimmune
bullous diseases. J Invest Dermatol E15–E32 (published online).
Matoltsy, A.G. 1975. Desmosomes, filaments, and keratohyaline granules:
their role in the stabilization and keratinization of the epidermis. J Invest
Dermatol. 65:127–142. (Describes the importance of desmosomes for
stability of epidermis and a method for isolating desmosomes from
epithelium later widely used to biochemically characterize desmosomes.
This method allowed identification of desmosomal proteins on which all
further biochemical and molecular work was based.)
BIOCHEMICAL AND MOLECULAR CHARACTERIZATION
OF DESMOGLEINS
Once a method of isolating desmosomes from epithelia
(cow’s snout was the major source) was established, they
could be biochemically characterized. The central part of the
desmosome, as seen by electron microscopy as a white area
between the cell membranes of adjacent cells, was thought to
be the ‘‘glue’’ that held the desmosomes (and, thereby, the
cells) together. When this area was enriched from the isolated
desmosomes, its protein composition could be determined. A
major protein was identified of about 160 kDa, and was
called desmoglein (Dsg), ‘‘glein’’ derived from the Greek
word for ‘‘glue’’.
Subsequently, antibodies against Dsg were developed.
These antibodies indicated that Dsg was found in desmo-
somes of various tissues across various species. Desmoglein,
therefore, was determined to be a widespread, and pre-
sumably important (i.e., conserved through evolution) com-
ponent of the desmosome. From this work, initially in
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epidermis, it was found that Dsg was also found in many
other tissues such as intestine, mammary gland, trachea,
bladder, liver, and, perhaps unexpectedly, heart and thymus.
Protein isolation and antibodies allowed molecular clon-
ing of Dsg. Surprisingly, Dsg was found to be a group of
homologous molecules encoded by a gene family. The most
interesting, and scientifically satisfying, finding was that Dsgs
belonged to a supergene family defined by classical
cadherins, which were already known to be calcium-
dependent adhesion proteins. Thus, Dsgs, thought to be a
part of the ‘‘glue’’ in desomomes, were found to be a part of a
family of adhesion molecules—a very nice convergence of
deductions from early morphological findings and newer
genetic cloning techniques.
The first two members of the Dsg gene family were
identified by genetic cloning as Dsg1 and 2, but a
dermatologic disease, pemphigus vulgaris, allowed identifi-
cation of a third member (see below), Dsg3. Analysis of the
human genome database identified another Dsg, Dsg4,
which was also identified by mutational analysis of a genetic
hair disease (localized autosomal recessive hypothrichosis;
Table 1).
Even at this early stage, characterization of a Dsg gene
family was closely intertwined with understanding skin
diseases. However, that interdependency reached another
level when the relationship of pemphigus with Dsgs was
defined.
Important JID references
Konohana, A., Konohana, I., Roberts, G.P., et al. 1987. Biochemical changes
in desmosomes of bovine muzzle epidermis during differentiation.
J Invest Dermatol 89:353–357. (Shows changes in Dsg amounts as
epidermis differentiates. This paper presaged the finding that a different
isoform of desmoglein was produced in more differentiated epidermis
and that desmoglein undergoes biochemical changes in the stratum
corneum that may be related to desquamation.)
Lundstrom, A., and Egelrud, T. 1990. Evidence that cell shedding from plantar
stratum corneum in vitro involves endogenous proteolysis of the
desmosomal protein desmoglein I. J Invest Dermatol 94:216–220. (More
evidence that degradation of desmoglein 1 occurs during desquamation.)
Roh, J.Y., and Stanley, J.R. 1995. Plakoglobin binding by human Dsg3
(pemphigus vulgaris antigen) in keratinocytes requires the cadherin-like
intracytoplasmic segment. J Invest Dermatol 104:720–724. (This report
determines which part of the desmoglein 3 tail binds to plakoglobin.)
Whittock, N.V., and Bower, C. 2003. Genetic evidence for a novel human
desmosomal cadherin, desmoglein 4. J Invest Dermatol. 120:523–530.
DESMOGLEINS IDENTIFIED AS TARGETS OF
AUTOANTIBODIES IN PEMPHIGUS
There are two major types of pemphigus, vulgaris and
foliaceus. In both, blisters are caused from loss of cell
adhesion in the deep epidermis or superficial epidermis,
respectively. Pemphigus vulgaris affects mucous membranes
and/or skin, whereas pemphigus foliaceus (PF) only affects
skin. In both, autoantibodies are known to directly mediate
the loss of cell adhesion.
The original discovery that these diseases are related to
desmosomes depended on a precious commodity, time,
which today (with increasing demands related to extensive
grant writing, extensive regulation, the geometric progression
of required educational modules for routine clinical, labora-
tory and animal work, demands to earn their salaries by
seeing patients, and more) is much less available. However,
the availability of time was the critical resource that allowed
one of the authors (JRS), in early 1980, to attend a lecture by
Malcolm Steinberg at Dulles Airport, 40minutes from where I
worked in Bethesda. At that time, I had been working on
identifying the autoantigen in PF and knew it was an
approximately 160 kDa protein as identified by SDS-PAGE
of epidermal extracts, followed by immunoblotting. This was
precisely the same time that Malcolm Steinberg (with G.
Gorbsky) was dissecting the proteins in the ‘‘desmoglea’’ (the
electron lucent center) of the desmosome. There was no
evidence then that pemphigus had anything to do with
desmosomes, but as cells come apart in pemphigus I was
interested in cell adhesion and, therefore, in desmosomes. As
I had enough time to attend that talk, I learned that Dr
Steinberg had identified the first Dsg, now called Dsg1, as a
160 kDa glycoprotein. Naively, I thought that it would make
Table 1. Desmogleins targeted in human diseases
Isoform Type Diseases
Desmoglein 1 Autoimmune Pemphgius foliaceus
Pemphigus vulgaris (mucocutaneous type)
Paraneoplastic pemphigus
Infection Staphylococcal scalded skin syndrome
Bullous impetigo
Genetic Striate palmoplantar keratoderma
Desmoglein 2 Infection Respiratory and urinary tract infection
(Receptors for adenovirus serotypes 3, 7, 11, and 14)
Genetic Arrythmogenic right ventricular cardiomyopathy
Dilated cardiomyopathy
Desmoglein 3 Autoimmune Pemphigus vulgaris (mucosal dominant type, mucocutaneous type)
Paraneoplastic pemphigus
Desmoglein 4 Genetic Hypotrichosis
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sense if Dsg1 was the PF antigen, because both were of the
same size as determined by SDS-PAGE. Ignorance is
also sometimes a great advantage to a scientist; I had no
idea how many molecules extracted from the epidermis
might migrate in the same general area on a one-dimensional
SDS-PAGE gel.
In fact, the PF antigen was ultimately shown to be Dsg1
(Figure 1), and was shown to be present in the superficial
epidermis. This finding showed the first autoimmune disease
of desmosomes, and had the scientifically satisfying logic that
an antibody against a presumed cell adhesion molecule in a
cell adhesion structure causes a disease from loss of cell
adhesion and subsequent blister formation.
At the time the PF antigen was shown to be Dsg1, the
pemphigus vulgaris antigen was only known to be a
glycoprotein of about 130 kDa, as determined by immuno-
precipitation. In addition, it was known that there was some
relationship of the pemphigus vulgaris antigen with desmo-
somes because it was shown by co-immunoprecipitation that
pemphigus vulgaris antigen co-precipitated plakoglobin with
the 130 kDa molecule. Similarly, PF sera co-precipitated
plakoglobin with Dsg1. Plakoglobin was known to be in the
plaque of the desmosome inside the cell. These studies were
the first to show that the tail of Dsgs (the part inside the cell)
bound a plaque protein of the desmosome. Again, a skin
disease, pemphigus, was intertwined with our growing
understanding of desmosomes, in this case their molecular
structure.
What really brought all these observations together, in
a beautiful and logical synthesis of previous findings, was
the molecular cloning of pemphigus vulgaris antigen,
which showed that it was another, previously unknown,
Dsg, now called Dsg3 (Figure 2). Although Dsg1 and 3
were both found in the epidermis, they were at different
levels; Dsg1 was superficial and Dsg3 was deep. All the
previous observations and findings now fit together nicely:
Pemphigus vulgaris and foliaceus were closely related
diseases in that both had loss of keratinocyte adhesion but
in different tissue localizations. The autoantibodies bound
closely related molecules thought to provide the ‘‘glue’’ in
adhesion structures, the desmosomes, with resultant loss
of adhesion and blisters. In pemphigus vulgaris and foli-
aceus, the blisters were thought to occur in different tissue
localizations because of the different localizations of the
Dsgs. Finally, both pemphigus antigens were found to bind
plakoglobin because Dsgs bind plakoglobin by their homo-
logous tails.
Many more subsequent studies confirmed that the anti-
Dsg antibodies in pemphigus patients cause the disease.
For example, adsorption of pemphigus sera with recom-
binant Dsgs resulted in loss of pathogenicity of those sera.
Monoclonal anti-Dsg antibodies cause disease when injected
into neonatal mice or human skin organ culture (Figure 3).
An interesting confirmation that loss of Dsg3 adhesion
causes pemphigus is that mice with a genetic deletion of
Dsg3 develop oral and skin lesions with the typical histology
of pemphigus vulgaris. Finally, specific proteolytic cleavage
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Figure 1. One of the major pieces of evidence that desmoglein 1 (Dsg1) is
the pemphigus foliaceus (PF) antigen. Two-dimensional gel electrophoresis of
extracts of the epidermis followed by immunoblotting with PF serum and an
anti-Dsg1 antibody shows that both identify spots with the same migration;
convincing proof that both bind the same protein (Koulu, L., Kusumi, A.,
Steinberg, M.S., et al. 1984. Human autoantibodies against a desmosomal
core protein in pemphigus foliaceus. J Exp Med 160:1509–1518.)
IEF, isoelectric focusing.
Figure 2. Original data from the cloning of pemphigus vulgaris antigen. (a) Purified lgt11 expression phage containing cDNA for pemphigus vulgaris
antigen. A single clone multiplies in bacteria, and all its offspring were blotted to nitrocellulose. All resultant clones stained positively with pemphigus
vulgaris sera. The cDNA was sequenced to show that the protein produced was desmoglein 3. (b) John Stanley (left) and Masayuki Amagai on the day in
1991 when the pemphigus vulgaris antigen clone was identified (Amagai, M., Klaus-Kovtun, V., and Stanley, J.R. 1991. Autoantibodies against a novel
epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869–877.)
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of Dsg1 caused lesions in the epidermis histologically
indistinguishable from PF (see below).
Important JID references
Stanley, J.R., Hawley Nelson, P., Poirier, M., et al. 1980. Detection of
pemphigoid antigen, pemphigus antigen, and keratin filaments by
indirect immunofluorescence in cultured human epidermal cells.
J Invest Dermatol 75:183–186. (Presence of pemphigus antigen in
keratinocyte culture indicated that such cells could be used for
immumoprecipation and immunoblotting to biochemically characterize
the antigens.)
Stanley, J.R., Klaus Kovtun, V., and Sampaio, S.A. 1986. Antigenic specificity
of fogo selvagem autoantibodies is similar to North American pemphigus
foliaceus and distinct from pemphigus vulgaris autoantibodies. J Invest
Dermatol 87:197–201.
Hashimoto, T., Ogawa, M.M., Konohana, A., et al. 1990. Detection of
pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot
analysis using different antigen sources. J Invest Dermatol 94:327–331.
(Immunoblotting has become an important approach to characterizing
autoimmune blistering skin diseases, including those with anti-desmo-
glein antibodies.)
Korman, N.J., Eyre, R.W., Zone, J., et al. 1991. Drug-induced pemphigus:
autoantibodies directed against the pemphigus antigen complexes are
present in penicillamine and captopril-induced pemphigus. J Invest
Dermatol 96:273–276. (Same desmoglein antigens are found in these
special types of pemphigus as in spontaneously occurring pemphigus.)
Rappersberger, K., Roos, N., and Stanley, J.R. 1992. Immunomorphological
and biochemical identification of the pemphigus foliaceus autoantigen
within desmosomes. J Invest Dermatol 99:323–330.
Olague-Alcala, M., Giudice, G.J., and Diaz, L.A. 1994. Pemphigus foliaceus
sera recognize an N-terminal fragment of bovine desmoglein 1. J Invest
Dermatol 102:882–885.
Emery, D.J., Diaz, L.A., Fairley, J.A., et al. 1995. Pemphigus foliaceus and
pemphigus vulgaris autoantibodies react with the extracellular domain of
desmoglein-1. J Invest Dermatol 104:323–328.
Kowalczyk, A.P., Anderson, J.E., Borgwardt, J., et al. 1995. Pemphigus sera
recognize conformationally sensitive epitopes in the amino-terminal
region of desmoglein-1 (Dsg1). J Invest Dermatol 105:147–152. (Many of
the pemphigus antibody-defined epitopes on desmogleins are conforma-
tional. This type of data led to the findings that pathogenic anti-
desmoglein antibodies tend to bind calcium-stabilized conformationally
sensitive epitopes.)
Shimizu, H., Masunaga, T., Ishiko, A., et al. 1995. Pemphigus vulgaris and
pemphigus foliaceus sera show an inversely graded binding pattern to
extracellular regions of desmosomes in different layers of human
epidermis. J Invest Dermatol 105:153–159.
Amagai, M., Koch, P.J., Nishikawa, T., et al. 1996. Pemphigus vulgaris
antigen (Desmoglein 3) is localized in the lower epidermis, the site of
blister formation in patients. J Invest Dermatol 106:351–355.
Memar, O.M., Rajaraman, S., Thotakura, R., et al. 1996. Recombinant
desmoglein 3 has the necessary epitopes to adsorb and induce blister-
causing antibodies. J Invest Dermatol 106:261–268.
Ding, X., Diaz, L.A., Fairley, J.A., et al. 1999. The anti-desmoglein 1
autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest
Dermatol 112:739–743.
Andl, C.D., and Stanley, J.R. 2001. Central role of the plakoglobin-binding
domain for desmoglein 3 incorporation into desmosomes. J Invest
Dermatol 117:1068–1074.
Ishii, K., Lin, C., Siegel, D.L., et al. 2008. Isolation of pathogenic monoclonal
anti-desmoglein 1 human antibodies by phage display of pemphigus
foliaceus autoantibodies. J Invest Dermatol 128:939–948. (Monoclonal
anti-desmoglein 1 antibodies cloned from a pemphigus foliaceus patient
cause blisters with typical histology in mice and human skin organ
culture.)
Yokouchi, M., Saleh, M.A., Kuroda, K., et al. 2009. Pathogenic epitopes of
autoantibodies in pemphigus reside in the amino-terminal adhesive
region of desmogleins which are unmasked by proteolytic processing of
prosequence. J Invest Dermatol 129:2156–2166.
DESMOGLEINS USED FOR THE DIAGNOSIS OF
PEMPHIGUS
cDNA isolation of Dsg1 and 3 allowed us to produce
recombinant proteins that properly reflect their three-dimen-
sional structures by baculovirus or mammalian expression.
The immunoadsorption of patients’ sera with those recombi-
nant proteins removed their immunoreactivities on KC cell
surfaces by immunofluorescence, as well as their ability to
induce blister formation in neonatal mice. Subsequently,
ELISA using recombinant Dsg1 and 3 were developed as a
serological diagnostic tool for pemphigus. Patients with PF
show only anti-Dsg1 IgG autoantibodies, whereas patients
with mucosal dominant type of pemphigus vulgaris have only
anti-Dsg3 IgG. Finally, patients with the mucocutaneous type
of pemphigus vulgaris have both anti-Dsg3 and anti-Dsg1
IgG. ELISA is a powerful and objective assay that allows easy
screening of large numbers of sera to characterize patients for
diagnosis and research purposes.
In general, ELISA antibody titers fluctuate in parallel with
the disease activity with time in any particular patient,
although the titers do not necessarily reflect the disease
severity among different patients. This discrepancy is because
patients’ sera are polyclonal, containing both pathogenic and
non-pathogenic antibodies for blister formation, as demon-
strated by isolation of mAbs from mice and humans. Such
pathogenicity, or the lack thereof, can be measured in
neonatal mice, in skin organ culture, or in KC dissociation
assays of cultured human KCs.
Important JID references
Amagai, M., Hashimoto, T., Green, K.J., et al. 1995. Antigen-specific
immunoabsorption of pathogenic autoantibodies in PF. J Invest Dermatol
104:895–901. (Proof that anti-desmoglein 1 antibodies in sera are
pathogenic.)
Ishii, K., Harada, R., Matsuo, I., et al. 2005. In vitro keratinocyte dissociation
assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG
autoantibodies in pemphigus vulgaris. J Invest Dermatol 124:939–946.
(This paper describes an assay, that has become widely used, to measure
pemphigus antibody pathogenicity.)
PATHOPHYSIOLOGY OF BLISTER FORMATION IN
PEMPHIGUS
There are two major, not necessarily exclusive, theories of
how pemphigus antibodies cause blisters. One theory is that
Figure 3. A monoclonal, monovalent anti-desmoglein 1 antibody cloned
from a pemphigus foliaceus patient (PF) causes typical histology of PF when
injected into normal human skin organ culture.
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antibodies cause steric hindrance of the Dsg adhesion site,
thus interfering directly with adhesion. The other theory is
that antibodies cause intracellular signaling that leads to loss
of adhesion.
Pemphigus antibodies cause steric hindrance
Epitope mapping of pemphigus autoantibodies and mAbs
from mice and humans has demonstrated that pathogenic
antibodies bind to the amino-terminal extracellular domain
of Dsgs, which is predicted to form the trans-adhesive
interface between cells, based on the crystal structures of
classic cadherins, molecules in the same gene family as Dsgs.
In addition, pathogenic PF mAbs cloned from patients bind to
the mature Dsg1, which reveals the active adhesion site only
after the proprotein is cleaved, but not to the proprotein that
does not form the adhesion site. So-called ‘‘knockout mice’’
lacking Dsg3 show similar, if not identical, acantholytic
lesions mimicking the phenotype of mucosal dominant type
of pemphigus vulgaris. These mice show that lack of function
(i.e., adhesion) of Dsg3, without antibody-induced signaling
(e.g., by crosslinking a cell surface receptor), indicates the
typical histology of pemphigus vulgaris. Desmoglein com-
pensation theory logically explains the site of blister
formation in the skin and mucous membranes in patients
with pemphigus, suggesting that blisters are formed as a result
of the loss of adhesive function of each Dsg isoform. If
antibody signaling caused loss of adhesion, then one would
expect that whenever antibodies bound Dsg3 a blister should
result because of the resultant signaling; yet, in fact, this is not
the case wherever Dsg1 is also present. These observations
suggest that pemphigus blisters are initially caused by steric
hindrance and not by the activation of a signaling pathway
that causes the initial loss of adhesion, although such
signaling may occur after loss of adhesion and may amplify
the initial loss of cell adhesion. Furthermore, these data do
not negate that modulation of signaling pathways that control
desmosome stability could be useful in counteracting
pemphigus antibody–induced loss of adhesion.
Pemphigus antibodies cause intracellular signaling
On the other hand, when pathogenic pemphigus antibodies
bind to the KC cell surface, several signaling events have
been shown to take place. The most widely studied are those
pathways that involve p38 mitogen-activated protein kinase
(p38MAP kinase) and plakoglobin. The most general indica-
tion of signaling is that pemphigus antibodies cause protein
phosphorylation changes in KCs. Studies of these changes
indicated that p38MAP kinase was a major pathway
stimulated by both pemphigus vulgairs and PF autoantibo-
dies. These pathways may be activated only after cells lose
their adhesion, but, even so, they probably increase the
acantholytic effects of pemphigus antibodies, and blocking
them may improve disease (see below). Another observation
regarding signaling in pemphigus was that KCs genetically
engineered to lack plakoglobin were not as susceptible to
pemphigus antibodies as were wild-type cells. This observa-
tion led to a pathway involving c-myc, which was shown to
be elevated in pemphigus antibody–stimulated keratinocytes.
Some of these signaling pathways are probably involved in
normal homeostasis of desmosomes and their components,
such as transport to the cell surface, into the desmosome, and
internalization. Pemphigus antibodies may function through
modulation of these physiological pathways. For example, as
a result of signals induced by pemphigus antibodies that
cause loss of Dsg adhesion as Dsgs reach the cell membrane,
Dsgs may be depleted first from the cell membrane, thereby
decreasing or eliminating the pool of Dsgs for their
incorporation into desmosomes, ultimately resulting in
depletion of Dsgs in desmosomes, leading to desmosome
dysfunction (i.e., acantholysis). Although it is difficult at this
time to detemine which are the most critical signaling
pathways contributing to pathogenicity, signaling pathways
may be an important target in designing therapy for
pemphigus in the future (see below).
Important JID references
Aoyama Y., Kitajima Y. (1999) Pemphigus vulgaris-IgG causes a rapid
depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble
pools, leading to the formation of Dsg3-depleted desmosomes in a
human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol
112:67–71.
Muller, E., Caldelari, R., de, B.A., et al. 2000. Pathogenesis in pemphigus
vulgaris: A central role for the armadillo protein plakoglobin. J Invest
Dermatol 115:332.
Williamson, L., Hunziker, T., Suter, M.M., et al. 2007. Nuclear c-Myc: a
molecular marker for early stage pemphigus vulgaris. J Invest Dermatol
127:1549–1555.
Berkowitz, P., Diaz, L.A., Hall, R.P., et al. 2008. Induction of p38MAPK and
HSP27 phosphorylation in pemphigus patient skin. J Invest Dermatol
128:738–740.
Mao, X., Choi, E.J., and Payne, A.S. 2009. Disruption of desmosome assembly
by monovalent human pemphigus vulgaris monoclonal antibodies.
J Invest Dermatol 129:908–918.
Jennings J.M., Tucker D.K., Kottke M.D., et al. 2011. Desmosome disassembly
in response to pemphigus vulgaris IgG occurs in distinct phases and can
be reversed by expression of exogenous Dsg3. J Invest Dermatol
131:706–718.
IMMUNOLOGY OF DEVELOPMENT OF ANTI-DSG
ANTIBODIES
Why do patients with pemphigus produce harmful auto-
antibodies against Dsgs? This is an ultimate and fundamental
question that we need to answer in the future. To begin to
address this question, upstream events of pathogenic anti-
body production have been investigated. It is probable that
both anti-Dsg B cells and Dsg-peptide–specific T cells that
provide help to those B cells are necessary for anti-Dsg
antibody formation. In support of this model, circulating B
cells producing anti-Dsg3 antibodies were detected by
enzyme-linked immunospot assay in patients. Circulating
T cells reacting with Dsg3 were detected in patients, but,
perhaps surprisingly, were also detected in normal people.
To investigate the formation of anti-Dsg antibodies in an
animal model, an active disease mouse model for pemphigus
vulgaris was developed by adoptive transfer of lymphocytes
from Dsg3-deficient mice to immune-deficient Dsg3-
expressing mice. This model was used to isolate anti-Dsg3
pathogenic mAbs, as well as Dsg3-specific T cells that
help B cells to produce pathogenic antibodies. Both the
T and B cells were needed for antibody formation. Aire
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(autoimmune regulator, a transcription factor) was also
shown to have a role in regulating Dsg3 expression in the
medullary thymic epithelial cells and in selection of
T cells in the thymus. Presumably, the expression of
Dsg3 in the thymus helps provide tolerance to that antigen
in most people.
Further clarification of the mechanisms for central and
peripheral tolerance to Dsg3-reacting T cells and B cells will
be an important step to develop antigen-specific immuno-
suppressive therapies.
Important JID references
Hertl M., Karr R.W., Amagai M., et al. 1998. Heterogeneous MHC II
restriction pattern of autoreactive desmoglein 3 specific T cell responses
in pemphigus vulgaris patients and normals. J Invest Dermatol 110:
388–392.
Nishifuji K., Amagai M., Kuwana M., et al. 2000. Detection of antigen-
specific B cells in patients with pemphigus vulgaris by enzyme-linked
immunospot assay: requirement of T cell collaboration for autoantibody
production. J Invest Dermatol 114:88–94.
Wada N., Nishifuji K., Yamada T., et al. 2011. Aire-dependent thymic
expression of desmoglein 3, the autoantigen in pemphigus vulgaris, and
its role in T-cell tolerance. J Invest Dermatol 131:410–417.
DESMOGLEINS ARE TARGETS IN INFECTIOUS DISEASES
The story of the identification of Dsg1 as the target of
staphylococcus-exfoliative toxin (Table 1) illustrates the
importance of having physicians as scientists.
The blisters in bullous impetigo and staphylococcal
scalded skin disease have been known for many years to be
caused by a toxin made and secreted by Staphylococcus
aureus, called exfoliative toxin. In bullous impetigo, the toxin
is produced locally, causing blisters at sites of infection. In
staphylococcal scalded skin syndrome, which is usually seen
in infants or very young children, the toxin circulates and
causes blisters distant from sites of infection. When injected
into mice, this toxin causes blisters. However, for many years
after its discovery, it was not clear how this toxin caused
blisters in the epidermis. Even after the toxin was molecularly
cloned and shown to have the structure of a serine protease
(i.e., a protease with a serine in its active site) that seemed to
need a specific substrate to orient its catalytic site to be
active, that substrate could not be identified. Ultimately, it
was dermatologists, with their knowledge of skin diseases,
who were able to solve this longstanding puzzle.
Even as early as the 18th century, astute clinicians who
were superb morphologists (probably because they had little
technology beyond their eyes and ears) recognized that
staphylococcal scalded skin syndrome resembled pemphigus.
Because of this observation, staphylococcal scalded skin
syndrome was sometimes called ‘‘pemphigus neonatorum’’.
In addition, it was known that injection of exfoliative toxin
into neonatal mice caused blisters whose histology was
identical to that resulting from injection of PF antibodies into
mice. In fact, any practicing dermatologist knows that
whenever a biopsy of a patient with PF is taken, the report
always indicates that although the histology is consistent with
PF, it is also consistent with bullous impetigo or staphylo-
coccal scalded skin syndrome. Once it was learned that PF
was caused by antibodies against Dsg1, it was a small step in
logic to hypothesize that exfoliative toxin’s protein substrate
might be Dsg1. In both cases the function of Dsg1 would be
impaired with similar resultant histology.
In fact, that simple but eloquent hypothesis was shown to
be correct. Exfoliative toxin was shown to cleave one peptide
bound in one substrate, Dsg1 (Figure 4). The use of this toxin
to enhance staphylococcus pathogenicity and infectivity is
beautiful in its simplicity. Essentially, staphylococcus has
evolved to produce a toxin that targets one peptide bond of
one molecule to enable it to grow under the stratum corneum
(the barrier of the skin), but enables it to be superficial enough
so that when one child touches another the bacteria can be
passed on.
Adenovirus provides another example of Dsg involvement
in infection. Most of the human adenoviruses (serotypes A
to F) use the coxsackie adenovirus receptor as a primary
attachment receptor. However, serotype B adenovirus, which
causes respiratory and urinary tract infections, does not use
this receptor, but has recently been found to bind to Dsg2 as
the primary high-affinity receptor (Table 1). Adenovirus
binding of Dsg2 triggers an epithelial-to-mesenchymal-like
transition, leading to transient opening of intercellular
junctions and penetration of virus into the subepithelial cell
layers and the blood stream, allowing the virus to spread.
Important JID references
Elias, P.M., Fritsch, P., Dahl, M.V., et al. 1975. Staphylococcal toxic
epidermal necrolysis: pathogenesis and studies on the subcellular site of
action of exfoliatin. J Invest Dermatol 65:501–512. (Exfoliative toxin
causes acantholysis similar to pemphigus antibodies.)
Amagai, M., Yamaguchi, T., Hanakawa, Y., et al. 2002. Staphylococcal
exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol
118:845–850.
DESMOGLEINS ARE TARGETS IN GENETIC DISEASES
Mutations in genes encoding Dsgs have also been described
in skin, hair, as well as in heart diseases (Table 1). Striate
Exfoliative toxin for
Extracellular domain
of desmoglein 1
0 1 5 10 20 60 120 (min)
Fragments
50 kda
34 kda
84 kDa
Figure 4. Coomassie blue gel showing cleavage of the 84-kDa extracellular
domain of desmoglein 1 to a 50 kDa and 34 kDa fragment, increasing
with time of incubation with exfoliative toxin A. (Hanakawa, Y., Schechter,
N.M., Lin, C., et al. 2004. Enzymatic and molecular characteristics of the
efficiency and specificity of exfoliative toxin cleavage of desmoglein 1.
J Biol Chem 279:5268–5277.)
www.jidonline.org 781
M Amagai and JR Stanley
Desmoglein in Human Diseases
palmoplantar keratoderma, an autosomal dominant disorder,
is characterized by longitudinal hyperkeratotic lesions on the
palms associated with focal or diffuse thickening of the
plantar skin. Haploinsufficiency mutations in the gene for
Dsg1, desmocollin 2, or desmoplakin, have been shown to
underlie this skin disorder. Mutations in the gene encoding
Dsg4 cause localized autosomal recessive hypothrichosis in
humans and the lanceolate hair phenotype in mice. More
recently, it has been discovered that arrhythmogenic right
ventricular cardiomyopathy, which is clinically characterized
by right ventricular enlargement and dysfunction, fibrofatty
replacement of myocytes in the right ventricle, characteristic
electrocardiographic abnormalities, ventricular arrhythmia,
and sudden death, is caused by mutations in the genes for
Dsg2, desmocollin 2, plakoglobin, plakophilin 2, or desmo-
plakin. These genetic findings underscore the importance of
Dsg (and other desmosomal molecules)-mediated adhesive
function in tissue integrity and function.
Important JID references
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DESMOGLEINS DO MORE THAN PROVIDE ADHESION
OF CELLS
Experiments showing that misexpression of Dsg isoforms
where they are not normally present causes differentiation
defects indicate that Dsgs may do more than simply provide
adhesion. For example, Dsg3 expression in the superficial
epidermis, where it is not normally present, causes abnormal
epidermal differentiation and stratum corneum formation
with increased transepidermal water loss. In mice with a
genetic deletion of Dsg2, there is a defect in blastocyst
proliferation resulting in failure of implantation. Conversely,
forced expression of Dsg2 in the superficial epidermis causes
increased proliferation. The above findings indicate profound
effects of Dsgs on KC proliferation and differentiation. At
present, it is thought that these effects are produced through
signal transduction pathways, although the exact pathways
have not been elucidated. One major contributor to signaling
through desmosomes may be plakoglobin. As discussed
above, Dsgs bind to plakoglobin, which is related to
b-catenin, a well-characterized molecule important in the
Wnt signaling pathway. This pathway is important in
proliferation and differentiation, as well as in embryological
development. The amount and the number of isoforms of Dsg
may control the amount of free plakoglobin that could
contribute to signaling. However, much work needs to be
done in the future to link signaling to specific molecules and
pathways.
Further evidence indicating that Dsgs do more than just
provide cell adhesion are the observations that demonstrate
that Dsg1 is critical for proper stratification and differentiation
of the epidermis. Interestingly, this effect, which is associated
with downregulations of the EGFR-Erk1/2 signaling pathway,
requires neither extracellular adhesion nor intracellular
plakoglobin binding. These results implicate pathways
independent of plakoglobin in Dsg signaling.
Important JID reference
Green, K.J., and Simpson, C.L. 2007. Desmosomes: new perspectives on a
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THE FUTURE: THERAPY OF PEMPHIGUS BASED ON THE
UNDERSTANDING OF ITS PATHOPHYSIOLOGY AND
IMMUNOLOGY
Anti-idiotypic therapy
Recent genetic analysis of mAbs cloned from pemphigus
vulgaris and foliaceus patients indicates that both pathogenic
and non-pathogenic mAbs are found, and that there are a
limited number of parenteral B-cell clones for these anti-
bodies. A limited set of, but comprising several different, Ig
variable heavy chain genes are used in patients to produce
pathogenic antibodies; therefore, it probably is not possible to
target variable heavy chains to treat the disease. However,
when the complementarity-determining region 3 (CDR3) of
the antibodies was analyzed, pathogenic antibodies shared
common sequences. The CDR3 region of antibodies is
thought to be the major region that binds the corresponding
antigen. Randomization and site-directed mutagenesis of the
heavy-chain CDR3 sequences in some of these antibodies
illustrated the importance of only a few, or even one, amino
acids for binding and/or pathogenicity. Such data suggest that
it might be possible to target common sequences in the CDR3
regions of pathogenic pemphigus antibodies to prevent
disease. Reagents derived from phage display cloning of
mAbs from patients could be used to screen for such blockers.
Important JID references
Payne, A.S., Siegel, D.L., and Stanley, J.R. 2007. Targeting pemphigus
autoantibodies through their heavy-chain variable region genes. J Invest
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Ishii, K., Lin, C., Siegel, D.L., et al. 2008. Isolation of pathogenic monoclonal
anti-desmoglein 1 human antibodies by phage display of pemphigus
foliaceus autoantibodies. J Invest Dermatol 128:939–948.
Rituximab
From knowledge that pemphigus is an autoantibody-
mediated disease with a limited set of anti-Dsg non-tolerant
B cells, as discussed above, it makes sense that eliminating B
cells might improve disease, especially if these non-tolerant
set of B cells cannot come back after B-cell depletion. In fact,
the success of rituximab for therapy tends to validate this
idea. Rituximab is an anti-CD20 antibody. CD20 is found on
all mature B cells, but not the stem B cells. B-cell pools are
repopulated from stem B cells (i.e., B cells that have not
formed Igs against specific antigens). Rituximab should,
therefore, in theory, eliminate anti-Dsg B-cell clones.
In fact, rituximab has shown excellent results in treating
pemphigus patients refractory to standard therapy (e.g.,
prednisone plus immunosuppressives such as azathioprine
or mycophenolate mofetil). A single cycle (two injections
over 2 weeks or four injections over a month) can lead to
complete remission in over 80% of patients, although some
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relapse and some may need low-dose prednisone therapy.
Rituxan causes a profound depletion of circulating B cells,
but presumably does not deplete plasma cells, which do not
have CD20 on their surface. As in most patients anti-Dsg
antibodies go down after rituximab therapy, the anti-Dsg
antibody–producing plasma cells may be short-lived and
need frequent replenishment by B cells.
In any case, elimination of circulating B cells has
proven to be excellent therapy for patients with refractory
pemphigus.
Important JID references
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Zambruno, G., and Borradori, L. 2008. Rituximab immunotherapy in
pemphigus: therapeutic effects beyond B-cell depletion. J Invest
Dermatol 128:2745–2747.
Signaling
As discussed above, pemphigus antibody binding to Dsg on
the KC cell surface causes signal transduction, which can
exacerbate acantholysis. Therefore, if the right signaling
pathways can be identified, then pharmacologically inter-
rupting them might be beneficial in patients. For instance,
blocking the p38MAP kinase pathway in a mouse model of
pemphigus has been shown to modulate disease.
In addition, studies, discussed above, have shown
that the normal system of cycling of desmosomal components
may be interrupted in pemphigus, causing depletion of
Dsg in desmosomes with subsequent acantholysis. Tools
might be found to perturb signaling to affect this physiolo-
gical process in order to increase Dsg synthesis and
subsequent incorporation into desmosomes, thereby stabiliz-
ing them and counteracting the depletion induced by
pemphigus antibodies. It may be that corticosteroids, which
are already known to be very effective in therapy, function by
this precise mechanism, in that they increase Dsg synthesis
through signaling.
Important JID reference
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